Brief: Compass Therapeutics Provides Regulatory Update On Tovecimig In Biliary Tract Cancer Following FDA Feedback
22/09/2026 14:12
BRIEF-Compass Therapeutics Provides Regulatory Update On Tovecimig In Biliary Tract Cancer Following FDA Feedback Sept 22 (Reuters) - Compass Therapeutics Inc. CMPX.O:
COMPASS THERAPEUTICS PROVIDES REGULATORY UPDATE ON TOVECIMIG IN BILIARY TRACT CANCER FOLLOWING FDA FEEDBACK
COMPASS THERAPEUTICS - FDA RECOMMENDS SURVIVAL BENEFIT TRIAL BEFORE BLA SUBMISSION FOR TOVECIMIG
COMPASS THERAPEUTICS - DOES NOT BELIEVE NEW TRIAL IS WARRANTED BEFORE BLA SUBMISSION FOR TOVECIMIG
COMPASS THERAPEUTICS - TO FURTHER ENGAGE WITH FDA ON BLA SUBMISSION FOR TOVECIMIG
COMPASS THERAPEUTICS - REMAINS CONFIDENT IN TOVECIMIG BASED ON SIGNIFICANT ORR AND PFS IMPROVEMENTS
Source text: ID:nGNX9VXbjK
Further company coverage: CMPX.O
((Reuters.Briefs@thomsonreuters.com))
Recent news on Compass Therapeutics
See all newsBrief: Compass Announces Inducement Grants Under Nasdaq Listing Rule
US RESEARCH ROUNDUP- Allstate, Autozone, Vertex Pharmaceuticals
U.S. STOCKS ON THE MOVE-Greenland Mines, GameStop, Shopify
U.S. STOCKS ON THE MOVE-Vicor, Thor Industries, Lennar
Brief: Compass Therapeutics Provides Regulatory Update On Tovecimig In Biliary Tract Cancer Following FDA Feedback